Loading
A phase 2/3 trial of Zilucoplan in childhood cancers, run by UCB Biopharma SRL, now recruiting.
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis is a phase 2/3 interventional study registered as NCT06055959 by UCB Biopharma SRL, with 8 participants planned, started 2024-10-16 and due to reach its primary completion in 2026-11-16. Interventions recorded: Zilucoplan.
Shares UCB, Childhood cancers (all types) and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.